Chris Rao Discusses the Impact of COVID-19 on Clinical Trials
Clinical trials have been heavily impacted by the COVID-19 crisis, affecting companies in all stages of development. Alira Health’s Christopher Rao, Vice President, Clinical Development, talks about the current disruption, the recently released FDA guidelines, and his best advice for companies who are in the midst of (or just starting) clinical trial work during this challenging time.
For more information, please contact Christopher Rao.
You might also be interested in:
The replay of our webinar: The COVID-19 Supply Shortage: Causes, Impact, and Solutions.
Click here to watch.
Download our latest report: COVID-19:
Alira Health makes no representations or warranties, either expressed or implied, as to the accuracy of the information in this report. Alira Health has collected and compiled the presented information on a best effort basis under time and budget constraints. In no event will Alira Health be held liable for any direct, indirect, incidental or consequential damages arising out of the use of the information in this report.
Unless otherwise explicitly stated, all information is copyrighted by Alira Health, irrespective of whether a copyright symbol and statement is present. All trademarks are acknowledged.